Page 133 - 《中国药房》2024年7期

mors：relationship between covariates and imatinib plasma mated homogeneous immunoassay for quantitating ima‐
trough level[J]. Front Surg，2023，10：1115141. tinib concentrations in plasma[J]. Ther Drug Monit，2015，
[25] YOO C，RYU M H，RYOO B Y，et al. Changes in ima‐ 37（4）：486-492.
tinib plasma trough level during long-term treatment of pa‐ [36] ESCUDERO-ORTIZ V， DOMÍNGUEZ-LEÑERO V，
tients with advanced gastrointestinal stromal tumors：cor‐ CATALÁN-LATORRE A，et al. Relevance of therapeutic
relation between changes in covariates and imatinib expo‐ drug monitoring of tyrosine kinase inhibitors in routine
sure[J]. Invest New Drugs，2012，30（4）：1703-1708. clinical practice：a pilot study[J]. Pharmaceutics，2022，14
[26] HOUK B E，BELLO C L，POLAND B，et al. Relationship （6）：1216.
between exposure to sunitinib and efficacy and tolerability [37] BIRCH M，MORGAN P E，HANDLEY S，et al. Simple
endpoints in patients with cancer：results of a pharmacoki‐ methodology for the therapeutic drug monitoring of the ty‐
netic/pharmacodynamic meta-analysis[J]. Cancer Che‐ rosine kinase inhibitors dasatinib and imatinib[J]. Biomed
mother Pharmacol，2010，66（2）：357-371. Chromatogr，2013，27（3）：335-342.
[27] SHIRAO K，NISHIDA T，DOI T，et al. Phase Ⅰ/Ⅱ study [38] GURJAR M，MEHTA P，SHARMA J，et al. An HPLC
of sunitinib malate in Japanese patients with gastrointesti‐ method for simultaneous quantification of sunitinib and its
nal stromal tumor after failure of prior treatment with ima‐ active metabolite，SU12662，using hydrophilic interaction
tinib mesylate[J]. Invest New Drugs，2010，28（6）： chromatography principle[J]. Bioanalysis，2020，12（2）：
866-875. 75-85.
[28] FAIVRE S，DELBALDO C，VERA K，et al. Safety，phar‐ [39] ETIENNE-GRIMALDI M C，RENÉE N，IZZEDINE H，
macokinetic，and antitumor activity of SU11248，a novel et al. A routine feasible HPLC analysis for the anti-
oral multitarget tyrosine kinase inhibitor，in patients with angiogenic tyrosine kinase inhibitor，sunitinib，and its
cancer[J]. J Clin Oncol，2006，24（1）：25-35. main metabolite，SU12662，in plasma[J]. J Chromatogr B
[29] YU H X，STEEGHS N，NIJENHUIS C M，et al. Practical Analyt Technol Biomed Life Sci，2009，877（29）：3757-
guidelines for therapeutic drug monitoring of anticancer 3761.
tyrosine kinase inhibitors：focus on the pharmacokinetic [40] FUJITA K，MIURA M，SHIBATA H. Quantitative deter‐
targets[J]. Clin Pharmacokinet，2014，53（4）：305-325. mination of regorafenib and its two major metabolites in
[30] WESTERDIJK K，KRENS S D，VAN DER GRAAF W T human plasma with high-performance liquid chromatogra‐
A，et al. The relationship between sunitinib exposure and phy and ultraviolet detection[J]. Biomed Chromatogr，
both efficacy and toxicity in real-world patients with renal 2016，30（10）：1611-1617.
cell carcinoma and gastrointestinal stromal tumor[J]. Br J [41] FORNASARO S，BONIFACIO A，MARANGON E，et al.
Clin Pharmacol，2021，87（2）：326-335. Label-free quantification of anticancer drug imatinib in hu‐
[31] POSOCCO B，BUZZO M，GIODINI L，et al. Analytical man plasma with surface enhanced Raman spectroscopy
aspects of sunitinib and its geometric isomerism towards [J]. Anal Chem，2018，90（21）：12670-12677.
therapeutic drug monitoring in clinical routine[J]. J Pharm [42] LAI K，XU T，YE Q L，et al. A hybrid SERS sensing plat‐
Biomed Anal，2018，160：360-367. form constructed by porous carbon/Ag nanoparticles for
[32] KOBAYASHI K，SUGIYAMA E，SHINOZAKI E，et al. efficient imatinib detection in bio-environment[J]. Spec‐
Associations among plasma concentrations of regorafenib trochim Acta A Mol Biomol Spectrosc，2023，300：122971.
and its metabolites，adverse events，and ABCG2 polymor‐ [43] LITTI L，AMENDOLA V，TOFFOLI G，et al. Detection
phisms in patients with metastatic colorectal cancers[J]. of low-quantity anticancer drugs by surface-enhanced Ra‐
Cancer Chemother Pharmacol，2021，87（6）：767-777. man scattering[J]. Anal Bioanal Chem，2016，408（8）：
[33] ROOD J J M，SCHELLENS J H M，BEIJNEN J H，et al. 2123-2131.
Recent developments in the chromatographic bioanalysis [44] 李永强. 通过表面增强拉曼进行人体体液分析的基底制
of approved kinase inhibitor drugs in oncology[J]. J 备与应用研究[D]. 成都：电子科技大学，2021.
Pharm Biomed Anal，2016，130：244-263. LI Y Q. Application and fabrication of substrates for hu‐
[34] SAITA T，SHIN M，FUJITO H. Development of a specific man body fluid analysis through surface-enhanced Raman
and sensitive enzyme-linked immunosorbent assay for the spectroscopy[D]. Chengdu：University of Electronic Sci‐
quantification of imatinib[J]. Biol Pharm Bull，2013，36 ence and Technology of China，2021.
（12）：1964-1968. （收稿日期：2023-10-21 修回日期：2024-02-04）
[35] BEUMER J H，KOZO D，HARNEY R L，et al. An auto‐ （编辑：唐晓莲）

中国药房 2024年第35卷第7期 China Pharmacy 2024 Vol. 35 No. 7 · 895 ·